FDA Strengthens Warning of Acute Kidney Injury related to Type 2 Diabetes Drugs

August 19, 2016 | Strategic Insights for Ambulatory Care


​The U.S. Food and Drug Administration (FDA) strengthened its existing warning about the risk of acute kidney injury related to the type 2 diabetes medications canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga, Xigduo XR), states a June 14, 2016, FDA safety alert. The agency has received 101 reports of acute kidney injury associated with canagliflozin or dapagliflozin use, some of which required hospitalization and dialysis.

Access Full Content

Contact us today at 610.825.6000.